Blair William & CO Beam Therapeutics Inc. Transaction History

Blair William & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$39.79 - $70.31 $39,790 - $70,310	-1,000 Reduced 15.89%	5,292 $252,000
Q1 2022 May 13, 2022	BUY	$53.73 - $82.16 $96,714 - $147,888	1,800 Added 40.07%	6,292 $361,000
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $50,470 - $73,502	742 Added 19.79%	4,492 $358,000
Q3 2021 Nov 12, 2021	BUY	$84.37 - $133.6 $37,966 - $60,120	450 Added 13.64%	3,750 $326,000
Q1 2021 May 13, 2021	SELL	$71.28 - $120.75 $32,076 - $54,337	-450 Reduced 12.0%	3,300 $264,000
Q4 2020 Feb 09, 2021	BUY	$22.24 - $95.63 $83,400 - $358,612	3,750 New	3,750 $306,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.